BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 16120623)

  • 41. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS).
    Samlowski WE; Watson GA; Wang M; Rao G; Klimo P; Boucher K; Shrieve DC; Jensen RL
    Cancer; 2007 May; 109(9):1855-62. PubMed ID: 17351953
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
    McDermott DF; Sosman JA; Gonzalez R; Hodi FS; Linette GP; Richards J; Jakub JW; Beeram M; Tarantolo S; Agarwala S; Frenette G; Puzanov I; Cranmer L; Lewis K; Kirkwood J; White JM; Xia C; Patel K; Hersh E
    J Clin Oncol; 2008 May; 26(13):2178-85. PubMed ID: 18445842
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
    Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
    Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].
    Cai Y; Wang WL; Xu B; Zhu GY; Zhang SW
    Ai Zheng; 2006 Nov; 25(11):1419-22. PubMed ID: 17094913
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
    Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma.
    Pyrhönen S; Hahka-Kemppinen M; Muhonen T
    J Clin Oncol; 1992 Dec; 10(12):1919-26. PubMed ID: 1280673
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
    Hwu WJ; Lis E; Menell JH; Panageas KS; Lamb LA; Merrell J; Williams LJ; Krown SE; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
    Cancer; 2005 Jun; 103(12):2590-7. PubMed ID: 15861414
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
    Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
    J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
    Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
    J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PCV chemotherapy for recurrent glioblastoma.
    Schmidt F; Fischer J; Herrlinger U; Dietz K; Dichgans J; Weller M
    Neurology; 2006 Feb; 66(4):587-9. PubMed ID: 16505319
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metastatic melanoma: case report of a patient with seventeen months of complete remission, five years survival and review of the literature.
    Samelis GF; Ekmektzoglou KA; Tsiakou A; Konstadoulakis MM
    J BUON; 2009; 14(4):717-20. PubMed ID: 20148469
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
    Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
    Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Treatment of metastasising melanoma with a combination of cytostatic agents (author's transl)].
    Kleeberg UR; Schreml W
    Dtsch Med Wochenschr; 1976 Jun; 101(23):890-4. PubMed ID: 1269431
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Chemotherapy of malignant melanoma].
    Ishihara K
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):23-7. PubMed ID: 7529980
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cisplatin-based chemotherapy for merkel cell carcinoma of the skin.
    Pectasides D; Pectasides M; Psyrri A; Koumarianou A; Xiros N; Pectasides E; Gaglia A; Lianos E; Papaxoinis G; Lampadiari V; Economopoulos T
    Cancer Invest; 2006 Dec; 24(8):780-5. PubMed ID: 17162559
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advanced mycosis fungoides: chemotherapy with etoposide, methotrexate, bleomycin, and prednimustine.
    Doberauer C; Ohl S
    Acta Derm Venereol; 1989; 69(6):538-40. PubMed ID: 2481928
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Chemotherapy of malignant melanoma--current status].
    Karg C; Garbe C; Orfanos CE
    Hautarzt; 1990 Feb; 41(2):56-65. PubMed ID: 2180855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
    Aleman BM; Raemaekers JM; Tomiŝiĉ R; Baaijens MH; Bortolus R; Lybeert ML; van der Maazen RW; Girinsky T; Demeestere G; Lugtenburg P; Lievens Y; de Jong D; Pinna A; Henry-Amar M;
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):19-30. PubMed ID: 17097834
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
    Spitler LE; Weber RW; Allen RE; Meyer J; Cruickshank S; Garbe E; Lin HY; Soong SJ
    J Immunother; 2009; 32(6):632-7. PubMed ID: 19483646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.